Tavalisse
Named-patient access overview. Tavalisse is coordinated by Reserve Meds for international patients via physician-led cross-border sourcing.
Quick orientation
Tavalisse (fostamatinib disodium hexahydrate) is an oral spleen tyrosine kinase (SYK) inhibitor developed by Rigel Pharmaceuticals. The US Food and Drug Administration approved Tavalisse in April 2018 for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment. The standard starting dose is 100 mg orally twice daily, increased to 150 mg twice daily after 4 weeks if platelet response is insufficient.
Case active and ready to skip the regulatory walkthrough? Start your case or WhatsApp us.
How Reserve Meds coordinates Tavalisse
- Patient or treating physician submits an intake at the patient portal.
- Reserve Meds clinical team verifies appropriateness for the patient and destination country.
- Treating physician issues prescription and clinical justification.
- Country-specific named-patient documentation is prepared.
- Tavalisse is sourced from a DSCSA-compliant US specialty wholesaler with full serial traceability.
- Shipment is coordinated to the patient's physician or hospital pharmacy with appropriate handling.
Access by country
Reserve Meds publishes a detailed country deep-dive for Tavalisse in every market we coordinate. Each page below covers the destination-country regulatory pathway, real costs, indicative timelines, physician-credential requirements, and handling notes. Tap any country to read the full deep-dive.
Start a request for Tavalisse
Submit a 60-second intake. The clinical team will follow up within 24 hours with case-specific feasibility, timeline, and a formal quote.